Search Results - "Sethunath, V"

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Drug-sensitive FGFR3 mutations in lung adenocarcinoma by Chandrani, P, Prabhash, K, Prasad, R, Sethunath, V, Ranjan, M, Iyer, P, Aich, J, Dhamne, H, Iyer, D N, Upadhyay, P, Mohanty, B, Chandna, P, Kumar, R, Joshi, A, Noronha, V, Patil, V, Ramaswamy, A, Karpe, A, Thorat, R, Chaudhari, P, Ingle, A, Choughule, A, Dutt, A

    Published in Annals of oncology (01-03-2017)
    “…Lung cancer is the leading cause of cancer-related deaths across the world. In this study, we present therapeutically relevant genetic alterations in lung…”
    Get full text
    Journal Article
  2. 2

    Abstract P4-03-04: Targeting the mevalonate pathway in HER2-positive breast cancer to overcome resistance to anti-HER2 therapy by Sethunath, V, Hu, H, De Angelis, C, Veeraraghavan, J, Qin, L, Rimawi, MF, Osborne, KC, Schiff, R

    Published in Cancer research (Chicago, Ill.) (15-02-2018)
    “…Abstract Background: Despite the advent of HER2-targeted therapies for HER2+ breast cancer (BC), including the monoclonal antibody trastuzumab (T) either alone…”
    Get full text
    Journal Article
  3. 3

    Abstract P6-17-12: Neratinib in combination with trastuzumab is superior to each alone and to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models by Veeraraghavan, J, Sethunath, V, Qin, L, Shea, MJ, Mitchell, T, De Angelis, C, Nanda, S, Diala, I, Lalani, AS, Hilsenbeck, SG, Rimawi, MF, Osborne, CK, Schiff, R

    Published in Cancer research (Chicago, Ill.) (15-02-2019)
    “…Abstract Background: Lapatinib (L) plus trastuzumab (T) alone or with endocrine therapy for HER2+/ER+ tumors but without chemotherapy, yielded complete tumor…”
    Get full text
    Journal Article
  4. 4

    Abstract P6-20-10: Role of GPR110 in breast cancer by Bhat, R, Qin, L, De Angelis, C, Sahay, D, Bhargava, D, Creighton, C, Yadav, P, Yazdanfard, S, Alrawi, A, Yadav, V, Vasaikar, S, Nanda, S, Sethunath, V, Fu, X, Zhang, B, Narkar, V, Schiff, R, Trivedi, M

    Published in Cancer research (Chicago, Ill.) (15-02-2019)
    “…Abstract Our long-term goal is to discover adhesion GPCR targets in breast cancer. Our previous studies have found GPR110 to be overexpressed in tumorigenic…”
    Get full text
    Journal Article
  5. 5

    Drug-sensitiveFGFR3 mutations in lung adenocarcinoma by Chandrani, P., Prabhash, K., Prasad, R., Sethunath, V., Ranjan, M., Iyer, P., Aich, J., Dhamne, H., Iyer, D.N., Upadhyay, P., Mohanty, B., Chandna, P., Kumar, R., Joshi, A., Noronha, V., Patil, V., Ramaswamy, A., Karpe, A., Thorat, R., Chaudhari, P., Ingle, A., Choughule, A., Dutt, A.

    Published in Annals of oncology (01-03-2017)
    “…Lung cancer is the leading cause of cancer-related deaths across the world. In this study, we present therapeutically relevant genetic alterations in lung…”
    Get full text
    Journal Article